Earnings History Data for Verve Therapeutics (VERV) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Verve Therapeutics

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2024	PM		VERV	Verve Therapeutics	857.00	-0.69	-0.80	0.00	Verve Therapeutics GAAP EPS of -$0.69 beats by $0.13, revenue of $5.14M beats by $3.97M [2/27/2024 7:47 AM]	17.47	3.03 (20.98%)	15.00	0.56 (3.87%)	8.22 - 21.42	1,993,424	960,000	3,680
Verve Therapeutics GAAP EPS of -$0.69 beats by $0.13, revenue of $5.14M beats by $3.97M [2/27/2024 7:47 AM]
07-11-2023	PM		VERV	Verve Therapeutics, Inc.	887.64	-0.72	-0.91	-0.79	Verve Therapeutics GAAP EPS of -$0.72 beats by $0.20, revenue of $3.12M beats by $2.04M [11/7/2023 8:21 AM]	18.77	3.79 (25.30%)	15.60	0.62 (4.14%)	8.52 - 27.93	2,883,806	1,680,000	2,191
Verve Therapeutics GAAP EPS of -$0.72 beats by $0.20, revenue of $3.12M beats by $2.04M [11/7/2023 8:21 AM] Verve shares surge to three-month high following Q3 update [11/7/2023 1:13 PM]
10-08-2023	PM		VERV	Verve Therapeutics	1,086	-0.87	-0.91	0.00	Verve Therapeutics GAAP EPS of -$0.87 beats by $0.05, revenue of $2.09M beats by $1.42M [8/10/2023 10:50 AM]	17.95	0.42 (2.40%)	0.0	0.0 (0.00%)	13.01 - 43.00	378,695	590,000	0
Verve Therapeutics GAAP EPS of -$0.87 beats by $0.05, revenue of $2.09M beats by $1.42M [8/10/2023 10:50 AM]
02-03-2023	PM		VERV	Verve Therapeutics	1,170	-0.67	-0.76	0.00	Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M [3/2/2023 6:56 AM]	20.20	2.01 (11.05%)	0.0	0.0 (0.00%)	10.70 - 43.00	1,105,791	660,000	0
Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M [3/2/2023 6:56 AM]
07-11-2022	PM	6:30 AM ET (Nov 7)	VERV	Verve Therapeutics	1,944	-0.79	-0.75	0.00	Verve Therapeutics GAAP EPS of -$0.79 misses by $0.06, revenue of $0.93M beats by $0.1M [11/7/2022 8:20 AM]	21.57	-9.72 (-31.08%)	24.00	-7.29 (-23.30%)	10.70 - 55.72	4,617,813	770,000	289,327
Verve sheds 22% as FDA holds trial application for gene editing drug [11/7/2022 7:16 AM] Verve Therapeutics GAAP EPS of -$0.79 misses by $0.06, revenue of $0.93M beats by $0.1M [11/7/2022 8:20 AM] Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results [Nov-07-22 06:30AM]
09-08-2022	PM		VERV	Verve Therapeutics	1,553	-0.84	-0.63	0.00	Verve Therapeutics GAAP EPS of -$0.84 misses by $0.20 [8/9/2022 8:34 AM]	28.27	1.10 (4.05%)	26.00	-1.17 (-4.31%)	10.70 - 78.00	618,574	970,000	1,175
Verve Therapeutics GAAP EPS of -$0.84 misses by $0.20 [8/9/2022 8:34 AM] Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results [Aug-09-22 06:30AM]
10-05-2022	PM		VERV	Verve Therapeutics	642.00	-0.62	-0.63	0.00		13.81	1.63 (13.38%)	13.38	1.20 (9.85%)	12.08 - 78.00	557,337	692,061	9,202
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results [May-10-22 06:30AM] Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022 [May-09-22 06:30AM]
14-03-2022	PM		VERV	Verve Therapeutics	1,346	-0.65	-0.54	0.00	Verve Therapeutics GAAP EPS of -$0.65 misses by $0.12 [3/14/2022 6:36 AM]	23.82	-2.45 (-9.33%)	26.27	0.0 (0.00%)	23.65 - 78.00	644,301	647,756	19,730
Verve Therapeutics GAAP EPS of -$0.65 misses by $0.12 [3/14/2022 6:36 AM] Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results [Mar-14-22 06:30AM]
10-11-2021	PM		VERV	Verve Therapeutics	2,395	-0.47	-0.45	0.00	Verve Therapeutics EPS beats by $0.05 [11/10/2021 6:43 AM]	49.28	-0.62 (-1.24%)	0.0	0.0 (0.00%)	29.50 - 78.00	278,424	230,000	0
Verve Therapeutics EPS beats by $0.05 [11/10/2021 6:43 AM] Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results [Nov-10-21 06:30AM] Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates [Nov-09-21 06:30AM]